Disruptive Drug Discovery
Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.
The Challenge
Traditional drug discovery efforts for CNS disorders have significant limitations. The CNS is a uniquely challenging field given the complexity of target tissue, and a translational gap exists where non-clinical models typically fail to reproduce human biology and deliver robust datasets. We have built our platform to traverse this gap.
Our Approach
We integrate powerful enabling technologies along three axes—advanced human biology, determinative measurement engineering, and algorithmic analysis—into a proprietary platform that redefines CNS drug discovery.
Our Vision
Our cutting-edge tools are generating the world's largest and most information-rich map of neuronal biology in both healthy and disease-states to bring forward transformational medicines for the CNS.
Leadership
Team
Adam Barnett, Ph.D.
Data Scientist / Senior Software Engineer
Nate Bremmer
Engineer I
Aishwarya Dhandapani
Associate Scientist
Joe Dwyer
Manager, Lab Operations
Noélle Germain, Ph.D.
Manager, Grants & Scientific Communication
Jennifer Grooms
Research Associate III
Lakshmi Hariharan
Manager, Accounting & Financial Systems
Karthiayani Harikrisnan
Scientist I
Benjamin Harwood, Ph.D.
Principal Scientist
Nina Heath
Senior Research Associate
Jane Jacques
Senior Production Manager
Caitlin Lewarch, Ph.D.
Senior Principal Bioinformatics Scientist
Josh Meier
Senior Research Associate
Aayush Shroff
Research Associate II
Fabricio Simao, Ph.D.
Principal Scientist
Mahdi Torkashvand, Ph.D.
Data Scientist
Eithne Walsh
Research Associate
Jianying Wang
Accountant, Accounts Payable
Dawei Zhang
Scientist II
